No Need to Panic, Says Serum Institute of India Amid Concerns About Oxford-Astrazeneca Test Bug
Amid concerns about the effectiveness of the Oxford vaccine after major drugmaker Astrazeneca admitted a dosing error, its partner at India Serum Institute of India (SII) said the candidate vaccine is safe and effective and that Indian trials progress smoothly with strict adherence to all protocols.
“The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are between 60 and 70%, making it a viable vaccine against the virus. With that said, varied age groups with different dosage forms will result in slight variations and efficacy. We must be patient and not panic, ”the Pune-based Serum Institute of India said in a statement.
Also read: AstraZeneca can run an additional test
“The Indian trials are running smoothly with strict adherence to all necessary processes and protocols. So far, there are no worries. However, we are reviewing the data that is available and will make further statements, if necessary, ”said SII.
The Astrazeneca-Oxford vaccine candidate became the third after Moderna, Pfizer to announce promising results to combat Covid-19. Claimed 70.4% efficacy overall – 90% efficacy on one dosing regimen when the vaccine was given as a half dose, followed by a full dose at least one month later, while another dosing regimen showed efficacy 62% when given in two full doses separated by at least one month.
Later, Astrazeneca admitted that giving half a dose and then a full dose, which showed 90 percent efficacy, was actually a dosing error.
As Astrazeneca plans to conduct additional trials, the Serum Institute of India has said that there is still no reason to be concerned when it comes to trials in India.
Prime Minister Narendra Modi visited the SII campus on Saturday to review the production mechanism of the Covid-19 vaccine and its distribution.